Coloplast stock edges higher as target raised and valuation debate intensifies
Published on 08/28/2026 at 19:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Coloplast A/S (ISIN DK0060448595) stock is trading in the mid-DKK460s on August 28, 2026, with investors weighing a new target price increase against a broader debate on whether the current valuation already prices in much of the company’s growth story. The shares closed at DKK459.00 in the most recent completed session before moving to an indicated DKK463.25 in intraday trading on Cboe Europe that day, pointing to a modest gain of 0.93 percent compared with the prior close as of August 28, 2026 per a market-data overview href='https://ch.zonebourse.com/actualite-bourse/coloplast-a-s-kepler-cheuvreux-a-l-achat-ce7858dfdf8cf422' title='Zonebourse overview of Coloplast August 28 2026' style='text-decoration:underline dotted;'>on Zonebourse. For investors, the mix of a gentle share-price move, fresh analyst commentary, and an ongoing valuation discussion is now the key backdrop heading into the next annual results.
Analyst lifts target while rating stays cautious
A fresh piece of news on August 28, 2026 is that an analyst has raised the target price on Coloplast stock to DKK470.00 from DKK450.00, while keeping a hold-type recommendation unchanged, according to an equity-research update href='https://ch.zonebourse.com/actualite-bourse/danske-bank-releve-l-objectif-de-cours-de-coloplast-a-470-couronnes-danoises-450-maintient-sa-rec-ce7858dfdd89fe27' title='Zonebourse report on Coloplast target raise' style='text-decoration:underline dotted;'>reported by Zonebourse. As of that August 28, 2026 note, the overview shows Coloplast trading at DKK466.40 intraday, implying upside of 0.77 percent to the new DKK470.00 target price if that level is reached. The same summary lists an average target price of DKK468.05, with the latest close at DKK459.00, indicating that the average target sits 1.97 percent above the last closing price as of August 28, 2026 according to the compiled estimates in that report href='https://it.marketscreener.com/notizie/danske-bank-alza-il-target-price-di-coloplast-a-470-dkk-da-450-confermando-il-rating-hold-bn-ce7858dfdd89fe27' title='MarketScreener note on Coloplast average target' style='text-decoration:underline dotted;'>summarized on MarketScreener. This combination of a cautious rating and limited percentage upside supports a narrative that the stock is regarded as fairly valued rather than deeply discounted.
On the same date, another research comment reiterates a positive stance on Coloplast stock, citing a supportive long-term case while acknowledging that the current share price leaves only a modest gap to the average target, as reflected by the DKK468.05 consensus figure compared with the DKK459.00 close href='https://ch.zonebourse.com/actualite-bourse/coloplast-a-s-kepler-cheuvreux-a-l-achat-ce7858dfdf8cf422' title='Zonebourse item on Coloplast positive view' style='text-decoration:underline dotted;'>in a further Zonebourse article. For investors, the quantified relationship between the stock’s current level and analyst targets matters: a 5.45 percent gain since the start of the year reported in the same data set, alongside a still negative performance of around minus 15 percent over the past year, illustrates how Coloplast has recovered part of earlier losses without yet returning to its prior peak. That uneven path is one reason why the valuation discussion has intensified.
Valuation debate and latest fundamentals
The valuation backdrop is highlighted in a long-form analysis published on August 28, 2026 that describes Coloplast as a strong business trading at a fair price where timing could be challenging for new buyers href='https://seekingalpha.com/article/4941110-coloplast-great-business-fair-price-bad-timing' title='Seeking Alpha analysis of Coloplast valuation' style='text-decoration:underline dotted;'>in a Seeking Alpha article. In that analysis, Coloplast is characterized as a high-quality medical-technology company with leading market positions, stable margins, and recurring revenue streams tied to chronic-care products, such as ostomy and continence-care devices. The author notes that, based on the most recently available referenced fiscal-year figures, Coloplast has historically generated attractive returns on invested capital and robust organic growth, but that the shares, at current price levels, imply valuation multiples that are neither clearly cheap nor extreme. The article therefore frames the stock as suitable for long-term holders who value quality, while cautioning that near-term upside may be limited if earnings do not significantly surprise to the upside.
From a fundamentals perspective, investors now look primarily to the next set of annual results. The same MarketScreener and Zonebourse data show that Coloplast’s next scheduled annual results release is on November 3, 2026, with that date highlighted as the upcoming annual 2026 publication in the event calendar href='https://ch.zonebourse.com/actualite-bourse/danske-bank-releve-l-objectif-de-cours-de-coloplast-a-470-couronnes-danoises-450-maintient-sa-rec-ce7858dfdd89fe27' title='Zonebourse calendar entry for Coloplast annual 2026 results' style='text-decoration:underline dotted;'>within the analyst note. Historical context cited in the valuation commentary indicates that in earlier recent fiscal years Coloplast delivered mid-to-high single-digit organic growth in revenue and maintained solid profitability, while also investing in emerging markets and product innovation to sustain future expansion. However, those earlier fiscal years fall outside the strict freshness window relative to August 28, 2026, and therefore serve as historical benchmarks rather than current metrics.
Looking ahead, the current consensus, as implied by the average target of DKK468.05 versus the last close at DKK459.00 and the intraday trading band around DKK462.50 to DKK466.40 on August 28, 2026, suggests that analysts see limited but positive potential upside over the coming months href='https://ch.zonebourse.com/actualite-bourse/coloplast-a-s-kepler-cheuvreux-a-l-achat-ce7858dfdf8cf422' title='Zonebourse data on Coloplast performance and targets' style='text-decoration:underline dotted;'>according to the latest performance table. That perspective is supported by the report showing a 5.45 percent rise since the start of the year paired with a roughly 14.66 to 15.36 percent decline over a longer trailing period, meaning that Coloplast has staged a partial recovery but remains below prior levels. For valuation-focused investors, this quantified gap between recent price performance and historical highs adds nuance: the stock is no longer deeply depressed, yet it does not sit at a record either, and the expected growth embedded in forecasts and targets must be delivered to justify further gains.
Market behavior and trading context
Shares of Coloplast trade primarily on the Copenhagen exchange in Danish kroner, with secondary trading venues such as Cboe Europe providing additional liquidity. On August 28, 2026, real-time estimations from Cboe Europe quoted the stock at around DKK462.50 to DKK466.40 in intraday dealings, marking day-on-day increases in the range of 0.76 to 1.61 percent compared with the previous close at DKK459.00, per the performance tables carried in the MarketScreener and Zonebourse entries noted above href='https://ch.zonebourse.com/actualite-bourse/danske-bank-releve-l-objectif-de-cours-de-coloplast-a-470-couronnes-danoises-450-maintient-sa-rec-ce7858dfdd89fe27' title='Zonebourse intraday price overview for Coloplast August 28 2026' style='text-decoration:underline dotted;'>as of the August 28, 2026 update. Those same tables also highlight a year-to-date gain of 5.45 to 6.43 percent and a negative longer-term performance of roughly minus 14.57 to minus 15.36 percent, underlining the contrast between short-term recovery and still-challenged twelve-month returns.
Intraday volatility appears contained, with movements on August 28, 2026 tracked in a relatively narrow DKK range and modest percentage changes. That behavior is consistent with a large, established healthcare issuer rather than a highly speculative small cap, and it fits the narrative from the valuation analysis that Coloplast’s stock is more sensitive to medium-term earnings revisions and guidance changes than to day-to-day shifts in sentiment. According to the MarketScreener performance summary on that date, Coloplast’s share-price path in recent sessions has seen incremental advances rather than sudden jumps, which, when combined with the limited spread between current levels and average analyst targets, suggests that the market is broadly aligned with consensus expectations for the time being href='https://it.marketscreener.com/notizie/danske-bank-alza-il-target-price-di-coloplast-a-470-dkk-da-450-confermando-il-rating-hold-bn-ce7858dfdd89fe27' title='MarketScreener performance and target data for Coloplast August 28 2026' style='text-decoration:underline dotted;'>as seen in the August 28, 2026 summary.
For traders, the proximity of the share price to the average target of DKK468.05 and the upper end of the recent intraday range around DKK466.40 refines the risk-reward calculation. Upside to the consensus target is small in absolute terms, while downside could emerge if earnings or guidance disappoint at the November 3, 2026 annual results release. On the other hand, if Coloplast’s upcoming report delivers stronger-than-expected organic growth, margin resilience, or new product traction in key segments such as ostomy or continence care, analysts may reassess their models and lift targets, potentially widening the gap between the trading price and fair value estimates. The interplay between those possibilities lies at the heart of the current valuation debate.
Medical devices supporting chronic-care patients
Coloplast’s business is centered on healthcare products that help patients manage chronic conditions and improve quality of life. Among its core offerings are ostomy-care systems designed for individuals who have undergone colostomy, ileostomy, or urostomy surgery and need reliable, skin-friendly solutions for waste collection. These systems typically include adhesive baseplates, flexible pouches, and accessories that reduce leakage risk and skin irritation, enabling users to maintain everyday activities with greater confidence. The company also provides continence-care products such as intermittent catheters and urine-collection devices, which help patients with bladder dysfunction or urinary incontinence manage symptoms discreetly and safely.
Another important product category is wound and skin care, where Coloplast supplies dressings and related technologies to support healing and protect vulnerable tissue. In this area, the company has focused on advanced materials and designs that promote moisture balance, reduce infection risk, and accommodate different wound types. Across these segments, Coloplast’s strategy emphasizes close collaboration with healthcare professionals and patient communities to design products that integrate comfortably into daily routines. For investors, the relevance of these products is not only clinical but also financial: chronic-care devices tend to generate recurring demand, providing revenue stability and underpinning the company’s long-term growth profile.
Coloplast stock and current market level
As of August 28, 2026, Coloplast stock is trading around DKK463 to DKK466 on Cboe Europe, compared with a last official close at DKK459.00 on the Copenhagen exchange, according to the latest performance tables href='https://ch.zonebourse.com/actualite-bourse/coloplast-a-s-kepler-cheuvreux-a-l-achat-ce7858dfdf8cf422' title='Zonebourse close and intraday ranges for Coloplast August 28 2026' style='text-decoration:underline dotted;'>displayed on Zonebourse. That puts the shares a short distance below the average target of DKK468.05 compiled in the August 28, 2026 analyst overview and leaves limited implied upside of roughly 0.77 to 1.97 percent depending on the exact intraday quote referenced href='https://ch.zonebourse.com/actualite-bourse/danske-bank-releve-l-objectif-de-cours-de-coloplast-a-470-couronnes-danoises-450-maintient-sa-rec-ce7858dfdd89fe27' title='Zonebourse comparison of Coloplast price to average target' style='text-decoration:underline dotted;'>within that report. For investors, this level suggests that Coloplast currently trades close to consensus fair value, with the next catalyst likely to be the annual 2026 results and any associated guidance updates on November 3, 2026.
Read more
Investor Relations href='https://www.coloplast.com/investor-relations/' title='Coloplast investor relations homepage' style='text-decoration:underline dotted;'>Coloplast investor relations
Chronic-care ostomy solutions
One representative product area reinforcing Coloplast’s long-term investment case is its ostomy-care portfolio, which includes systems designed to provide comfort, discretion, and skin protection for patients who live permanently with a stoma after colorectal or urinary-tract surgery. These products combine advanced adhesive technology with flexible materials and user-friendly designs, allowing wearers to move, work, and exercise with reduced worry about leakage or odor. Over time, iterative improvements in baseplate materials, pouch shapes, and filter systems have helped Coloplast maintain competitive differentiation and respond to feedback from both nurses and patients.
The ostomy-care segment also illustrates the company’s focus on education and support. Coloplast provides training materials and services for healthcare professionals to ensure that products are fitted correctly and that patients receive guidance on everyday management. The resulting ecosystem deepens relationships with hospitals and clinics and can drive brand loyalty among users, supporting recurring demand. While specific revenue or margin figures for this segment in the latest fiscal year are not visible in the August 28, 2026 source set, historical commentary indicates that ostomy and continence care together represent a significant share of Coloplast’s business and have been key contributors to its growth and profitability over multiple reporting periods.
Current share-price context for investors
For investors evaluating Coloplast stock on August 28, 2026, the immediate picture is of a high-quality healthcare issuer trading slightly below the average analyst target but above levels seen at the start of the year. The shares closed at DKK459.00 in the most recent completed session and are quoted in intraday trading in a range centered around DKK463.25 to DKK466.40, implying a day-on-day gain of between 0.93 and 1.61 percent and a year-to-date performance of between 5.45 and 6.43 percent, while longer-term returns over the past year remain negative at roughly minus 14.57 to minus 15.36 percent href='https://it.marketscreener.com/notizie/danske-bank-alza-il-target-price-di-coloplast-a-470-dkk-da-450-confermando-il-rating-hold-bn-ce7858dfdd89fe27' title='MarketScreener detailed performance data for Coloplast August 28 2026' style='text-decoration:underline dotted;'>as shown in the August 28, 2026 performance tables. Against that backdrop, the newly raised target of DKK470.00 and the average target of DKK468.05 provide a modest cushion.
Fact box
Company: Coloplast A/S
ISIN: DK0060448595
Ticker: COLO-B
Exchange: Nasdaq Copenhagen
Price (as of August 28, 2026, intraday Cboe Europe estimate): DKK466.40
Market cap: Data not specified in the available sources
Sector / Industry: Healthcare - Medical devices
Index membership: OMX Copenhagen large-cap
More on products
Coloplast’s chronic-care devices, particularly in ostomy and continence segments, are widely used in hospitals and home-care settings and have helped the company build a durable revenue base supported by recurring demand for consumable products.
